65,437 trials
Postoperative Pulmonary Complications
Primary: Number and Severity of Postoperative Pulmonary Complications Between Participant Groups — 84; 73; 35; 51 complications
Normal Physiology
Primary: Memory Performance — 0.89; 0.64; 0.91; 0.66 proportion accuracy
Type 2 Diabetes Mellitus
Primary: Number of Enrollees With Diabetes-related Preventable Hospitalizations — 48; 109; 48; 90 Participants
Hematologic Malignancies
Primary: GVHD-free Relapse-Free Survival — 19.3 percentage of subjects
Choroidal Ischemia · Vitelliform Macular Dystrophy · Age-related Macular Degeneration
Primary: Change in Visual Acuity (Sildenafil Group) — 0.00; -0.03 logMAR
Loneliness
Primary: Change in Loneliness — 4.64; 4.65; 4.82; 4.62 units on a scale
Dry Eye Disease (DED)
Primary: Thickness of the Mucus-aqueous Tear Film Layer — 3920.3 nm
Cerebral Palsy
Primary: Device Feasibility — 33.33 percent time EMG taVNS stimulation
Functional Abdominal Pain
Primary: Number of Participants Who Complete Treatment — 22 Participants
Pre-diabetes · Breast Cancer · Time Restricted Feeding
Primary: Change in Advanced Glycation End Products (AGE) as Assessed by Plasma — 5.82; 6.38; 5.82; 6.40 ng/mL
HIV · Alcohol Use
Primary: Enrollment to Assess Feasibility — 50 Participants
Hookworm Infection · Hookworm Disease
Primary: Vaccine-related Adverse Events — 1; 3; 0; 3 Participants
Lennox Gastaut Syndrome
Primary: Part 1: Percent Change From Baseline in the Frequency of Seizures That Result in Drops (ESC-confirmed) in the Combined Titration and Maintenance Period (T+M) in the…
Mild Cognitive Impairment
Primary: Gait Speed During the Single Task — 0.17; 0.09; 0.00; 0.15 m/s — p=0.003
Congenital Afibrinogenemia · Congenital Hypofibrinogenemia
Primary: Single-dose Pharmacokinetics (PK) of BT524: Terminal Elimination Half-life (t1/2) for Fibrinogen Antigen — 67.9 hours